Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03251144 · ClinicalTrials.gov registry record · Phase 1
Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)
A Phase 1 study of HIV/AIDS and Mitochondrial Alteration, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT03251144 is a Phase 1 study of HIV/AIDS and Mitochondrial Alteration that has completed, run by University of California, Los Angeles. The registered enrollment target is 26 participants, below the 33,180-participant average among 61 other HIV/AIDS trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03251144, a Phase 1 study of HIV/AIDS and Mitochondrial Alteration, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
Increased comorbidities such as cardiovascular disease (CVD), are emerging problems in HIV infection but the mechanisms are unclear. Understanding how antiretrovirals can minimize morbidity in treated HIV infection is a research priority. Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) are included in all HIV treatment regimens. Tenofovir (TFV) disoproxil fumarate (TDF) has been associated with an increased risk of nephrotoxicity and bone disease compared with other NRTIs. Tenofovir alafenamide (TAF) is an oral prodrug of TFV, but is more stable in plasma as compared with TDF and lower plasma levels of TFV are thought to lead to the favorable safety profile of TAF. Mitochondrial dysfunction has a key role in HIV pathogenesis and may be the common denominator that drives pathogenesis of several comorbidities. Despite the better safety profile of newer (such as TDF) compared to older NRTIs, there are concerns for the potential for longer term toxicity of NRTIs since the exact cellular effects of NRTIs remain unclear. It is unknown whether a four-fold increase in intracellular drug levels seen in peripheral blood mononuclear cells (PBMCs) with TAF may increase toxicity in mitochondria. Better understanding of these effects could provide insights into mechanisms of HIV pathogenesis and selection of NRTIs that improve morbidity in chronic HIV infection. Hypothesis: Despite higher intracellular levels, TAF has minimal mitochondrial toxicity compared to TDF in vivo. This research will explore the relative mitochondrial toxicity of newer NRTIs (TAF, TDF) as a possible mechanism for differential NTRI-related toxicities. These data will allow selection of NRTIs that may improve morbidity in chronic treated HIV infection. Towards this aim, the investigators will use a robust experimental approach to study NRTI-related mitochondrial dysfunction using novel methods, human cell lines and PBMC. Our specific aims are: Aim 1: To evaluate the relative in vitro effects
Conditions Studied
Interventions
- DRUG Switch to E/C/FTC/TAF daily
Study Locations (1)
California
- UCLA CARE Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2021-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03251144
The ClinicalTrials.gov registry entry for NCT03251144 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 33,180-participant average among 61 other HIV/AIDS trials with a reported enrollment target (100% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with HIV/AIDS appearing as the primary indexed condition, and to 1 intervention - of which Switch to E/C/FTC/TAF daily is the first listed.
NCT03251144 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03251144 about?
NCT03251144 is a clinical study titled "Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)". Increased comorbidities such as cardiovascular disease (CVD), are emerging problems in HIV infection but the mechanisms are unclear. Understanding how antiretrovirals can minimize morbidity in treated HIV infection is a research priority. Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs...
What is the current status of trial NCT03251144?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2019-04-01. Estimated completion is 2021-07-01.
What conditions does trial NCT03251144 study?
This clinical trial studies the following conditions: HIV/AIDS, Mitochondrial Alteration, Antiviral Toxicity, Antiviral Drug Adverse Reaction.
What interventions are being tested in trial NCT03251144?
The interventions under investigation include: Switch to E/C/FTC/TAF daily (DRUG).
Who is sponsoring clinical trial NCT03251144?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03251144 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV/AIDS
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Combinatorial Therapy to Induce an HIV Remission
ACTIVE NOT RECRUITING · Phase 1
-
Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal Tissue
COMPLETED · Phase 1
-
Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis Regimens
COMPLETED · Phase 1
-
Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - PK Study
COMPLETED · Phase 1
-
A Mobile Gaming App to Improve Adherence to PrEP
RECRUITING · NA
-
LinkPositively+ A Mobile Health App Delivered Intervention to Improve HIV Care Outcomes Among Black Women Affected by Mental Health and Violence
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.